Athira Pharma Announces Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Author: Benzinga Newsdesk | December 12, 2023 08:02am
Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson's disease dementia and dementia with Lewy Bodies.
Posted In: ATHA